CIGB 210

Drug Profile

CIGB 210

Latest Information Update: 25 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Class
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 31 Dec 2014 Preclinical trials in HIV infections in Cuba (unspecified route) prior to December 2014
  • 01 Dec 2014 CIGB 210 is available for licensing as of 01 Dec 2014.
  • 31 Dec 2013 CIGB has patent protection for CIGB 210 in Cuba (granted prior to December 2013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top